<DOC>
	<DOCNO>NCT01704651</DOCNO>
	<brief_summary>This study design determine whether oral perioperative medication ( alvimopan -- selective mu antagonist ) improve bowel recovery placebo surgery ovarian cancer .</brief_summary>
	<brief_title>Accelerating Gastrointestinal Recovery</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Alvimopan</mesh_term>
	<criteria>Inclusion criterion : Females least 18 year age Have American Society Anesthesiologists ( ASA ) Score I III Are consent primary , interval , secondary cytoreduction ovarian , tubal , peritoneal cancer Are schedule nasogastric tube remove first postoperative dose study medication Are able understand study procedure , agree participate study program , voluntarily provide informed consent Exclusion criterion : Females young 18 year age Known nongynecologic malignancy present similar signs/symptoms ovarian , tubal , peritoneal cancer . Have take 7 consecutive day therapeutic dos opioids immediately prior surgery Use illicit drug abuse alcohol Have prior total colectomy , gastrectomy , gastric bypass , functional colostomy ileostomy Have ongoing history short bowel syndrome , chronic constipation ( â‰¤3 spontaneous bowel movement per week ) chronic diarrhea Have receive radiation therapy abdomen pelvis within 3 month schedule surgery Have chemotherapy radiation induce bowel dysfunction Are pregnant ( identify positive urine serum pregnancy test ) lactating , postmenopausal ( menses least 1 year ) childbearing potential use accepted method birth control ( ie , surgical sterilization , intrauterine contraceptive device , oral contraceptive , diaphragm , condom combination contraceptive cream , jelly , foam , abstinence ) Have participate another investigational drug medical device study within 30 day surgery enrol another investigational drug medical device study study active patient participation require outside normal hospital data collection course study Have clinically significant laboratory abnormality screen would result cancellation surgery Have diagnosis severe hepatic insufficiency end stage renal disease . Have history previous surgery , illness , behavior opinion investigator might confound study result pose additional risk administer study procedure Are unable understand study procedure able voluntarily provide informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ovary</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Fallopian</keyword>
	<keyword>Peritoneal</keyword>
	<keyword>Cancer</keyword>
	<keyword>Gynecological</keyword>
	<keyword>Female</keyword>
</DOC>